Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Clovis Oncology Inc (CLVS)

Clovis Oncology Inc (CLVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 502,316
  • Shares Outstanding, K 88,203
  • Annual Sales, $ 143,010 K
  • Annual Income, $ -400,420 K
  • 60-Month Beta 2.28
  • Price/Sales 3.68
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -1.01
  • Number of Estimates 5
  • High Estimate -0.88
  • Low Estimate -1.11
  • Prior Year -1.89
  • Growth Rate Est. (year over year) +46.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.77 +23.27%
on 09/04/20
7.97 -26.22%
on 09/17/20
+0.79 (+15.52%)
since 08/25/20
3-Month
4.70 +25.11%
on 08/12/20
7.97 -26.22%
on 09/17/20
-1.43 (-19.56%)
since 06/25/20
52-Week
2.93 +100.68%
on 10/28/19
17.37 -66.15%
on 12/02/19
+1.70 (+40.67%)
since 09/25/19

Most Recent Stories

More News
Glaxo's Zejula Gets Positive CHMP View for First-Line Setting

The CHMP's favorable response recommends the regulatory nod for GlaxoSmithKline's (GSK) Zejula as the first-line maintenance treatment of ovarian cancer patients regardless of the biomarker status.

AZN : 55.51 (+2.47%)
MRK : 82.93 (-0.26%)
GSK : 37.80 (+1.12%)
CLVS : 5.88 (+3.25%)
New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the data being presented as e-posters at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. These include initial data from the...

CLVS : 5.88 (+3.25%)
Clovis Oncology Announces Oral Plenary Session Presentation at International Gynecologic Cancer Society (IGCS) Digital Annual Global Meeting

Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that an abstract featuring data from an exploratory analysis of the ARIEL3 clinical study evaluating Rubraca(R) (rucaparib) as maintenance treatment...

CLVS : 5.88 (+3.25%)
Clovis Oncology to Highlight Data for its Three Portfolio Compounds at the ESMO Virtual Congress 2020

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that six e-posters highlighting clinical data from the lucitanib and Rubraca(R) (rucaparib) clinical development programs, as well as preclinical data...

CLVS : 5.88 (+3.25%)
Five Pharmaceutical Stocks Investors May Want to Keep an Eye On

"Glioblastoma is the most common and aggressive cancerous brain tumour in adults due to its resistance ...

ABBV : 86.23 (+0.37%)
IMAB : 38.22 (-2.43%)
DFFN : 0.8300 (+4.34%)
AZN : 55.51 (+2.47%)
CLVS : 5.88 (+3.25%)
WBIO.CN : 0.275 (-5.17%)
Clovis Oncology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on...

CLVS : 5.88 (+3.25%)
Shares of CLVS Down 28.2% Since Downtrend Call on Shares

SmarTrend identified a Downtrend for Clovis Oncology (NASDAQ:CLVS) on May 20th, 2020 at $7.35. In approximately 4 months, Clovis Oncology has returned 28.23% as of today's recent price of $5.28.

CLVS : 5.88 (+3.25%)
Are Options Traders Betting on a Big Move in Clovis Oncology (CLVS) Stock?

Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.

CLVS : 5.88 (+3.25%)
FDA Approves FoundationOne(R) Liquid CDx to Serve as Rubraca(R) (rucaparib) Companion Diagnostic to Identify Eligible Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) approved the FoundationOne(R) Liquid CDx, Foundation Medicine's comprehensive liquid biopsy test for...

FMI : 136.95 (-0.04%)
CLVS : 5.88 (+3.25%)
Clinical Trials Testing New Paradigms For Advanced Therapies Treating Metastatic Cancer Conditions

, /PRNewswire/ -- Various reports on the global metastatic cancer treatment market all project continued growth in the next several years. One such report from Industry Research says that the global metastatic...

CNSP : 1.8500 (+5.11%)
MNTA : 52.40 (+0.02%)
JNJ : 145.66 (+0.68%)
ABBV : 86.23 (+0.37%)
BMY : 59.49 (+2.13%)
CLVS : 5.88 (+3.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade CLVS with:

Business Summary

Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations....

See More

Key Turning Points

2nd Resistance Point 6.15
1st Resistance Point 6.01
Last Price 5.88
1st Support Level 5.66
2nd Support Level 5.45

See More

52-Week High 17.37
Fibonacci 61.8% 11.85
Fibonacci 50% 10.15
Fibonacci 38.2% 8.45
Last Price 5.88
52-Week Low 2.93

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar